SEATTLE, May 1 Trubion Pharmaceuticals, Inc.(Nasdaq: TRBN), today announced it plans to issue earnings results for thefirst quarter ended March 31, 2008, after the close of market on May 8, 2008.The company's earnings conference call will take place May 8, 2008, at 2 p.m.PDT (5 p.m. EDT).
Both live events will be available for viewing on Trubion's website athttp://investors.trubion.com/events.cfm.
First-Quarter Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, May 8,2008
Participants are invited to call 1(877) 545-1488 or 1 (719) 325-4899. Areplay of the discussion will be available after 5 p.m. PDT / 8 p.m. EDT byvisiting Trubion's website or by calling 1(888) 203-1112 or 1 (719) 457-0820,and entering 7602146. The replay will be available until midnight, Monday,May 12.
Trubion is a biopharmaceutical company that is creating a pipeline ofnovel protein therapeutic product candidates to treat autoimmune andinflammatory diseases and cancer. The company's mission is to develop avariety of first-in-class and best-in-class product candidates, customized foroptimal safety, efficacy, and convenience that it believes may offer improvedpatient experiences. Trubion's current product candidates are novelsingle-chain protein, or SMIP(TM), therapeutics, and are designed using itscustom drug assembly technology. Trubion's product pipeline includesCD20-directed candidates such as TRU-015 and SBI-087 for autoimmune andinflammatory diseases, developed under the company's Wyeth collaboration.Trubion's proprietary product candidate, TRU-016, is a novel CD37-targetedtherapy for the treatment of B-cell malignancies currently in Phase 1/2clinical evaluation. In addition to Trubion's current product candidates, thecompany is also developing additional alliance and proprietary productcandidates that build on its product development experience. More informationis available in the investors section of Trubion's website:investors.trubion.com.Jim DeNike Senior Director, Corporate Communications Trubion Pharmaceuticals, Inc. (206) 838-0500 [email protected]
SOURCE Trubion Pharmaceuticals, Inc.